Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Descrição
PDF] MGAT2, a Monoacylglycerol Acyltransferase Expressed in the
Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the
Beyond triglyceride synthesis: the dynamic functional roles of
The monoacylglycerol acyltransferase pathway contributes to
Inhibition of MGAT2 modulates fat‐induced gut peptide release and
Ablation of the deubiquitinase USP15 ameliorates nonalcoholic
Therapeutic Strategies for Metabolic Diseases: Small‐Molecule
Nonalcoholic Fatty Liver Disease: The Overlooked Complication of
Inhibition of MGAT2 modulates fat‐induced gut peptide release and
Frontiers New insights into the role of dietary triglyceride
MGAT2 inhibitor decreases liver fibrosis and inflammation in
Pharmacotherapies of NAFLD: updated opportunities based on
Targeted therapeutics and novel signaling pathways in non-alcohol
New Drugs on the Block—Emerging Treatments for Nonalcoholic
US9701672B2 - Dihydropyridinone MGAT2 inhibitors for use in the
de
por adulto (o preço varia de acordo com o tamanho do grupo)
